|
|
1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached: ii |
Allergy Therapeutics PLC |
2 Reason for the notification (please tick the appropriate box or boxes): |
An acquisition or disposal of voting rights |
X |
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
An event changing the breakdown of voting rights |
|
Other (please specify): |
|
|
3. Full name of person(s) subject to the
notification obligation: iii |
Abbott Laboratories, an Illinois corporation (for further see, section 9) |
4. Full name of shareholder(s)
(if different from 3.):iv |
CFR International SPA and Yissum Holding Limited (for further, see section 9) |
5. Date of the transaction and date on
which the threshold is crossed or
reached: v |
26 September 2014 |
6. Date on which issuer notified: |
29 September 2014 |
7. Threshold(s) that is/are crossed or
reached: vi, vii |
Over 48% |
8. Notified details: |
A: Voting rights attached to shares viii, ix |
Class/type of
shares
if possible using
the ISIN CODE
|
Situation previous
to the triggering
transaction |
Resulting situation after the triggering transaction |
Number
of
Shares |
Number
of
Voting
Rights |
Number
of shares |
Number of voting
rights |
% of voting rights x |
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
Ordinary shares GBP 0.01 GB00B02LCQ05 |
Below 3% |
Below 3% |
N/A |
N/A |
198,710,723 |
N/A |
48.5% |
|
|
B: Qualifying Financial Instruments |
Resulting situation after the triggering transaction |
Type of financial
instrument |
Expiration
date xiii |
Exercise/
Conversion Period xiv |
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted. |
% of voting
rights |
|
|
|
|
|
|
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
Resulting situation after the triggering transaction |
Type of financial
instrument |
Exercise price |
Expiration date xvii |
Exercise/
Conversion period xviii |
Number of voting rights instrument refers to |
% of voting rights xix, xx |
|
|
|
|
|
Nominal |
Delta |
|
|
|
Total (A+B+C) |
Number of voting rights |
Percentage of voting rights |
198,710,723 |
48.5% |
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi |
Through a series of controlled undertakings, Abbott Laboratories has an indirect holding of 99.9% of the shares in CFR Pharmaceuticals, SA. CFR Pharmaceuticals SA's wholly owned subsidiary, CFR International SPA, holds 14.98% of the voting rights in Allergy Therapeutics plc directly and 33.53% of the voting rights in Allergy Therapeutics plc indirectly. CFR International SPA also has a 100% interest in Yissum Holding Limited, which directly holds 33.53% of shares in Allergy Therapeutics plc. |
|
Proxy Voting: |
10. Name of the proxy holder: |
|
11. Number of voting rights proxy holder will cease
to hold: |
|
12. Date on which proxy holder will cease to hold
voting rights: |
|
|
13. Additional information:
|
|
14. Contact name: |
Laura Bentham Baker & McKenzie LLP |
15. Contact telephone number: |
+44(0)207 919 1000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|